CN1772743A - Antifungal compound and its prepn process and application - Google Patents
Antifungal compound and its prepn process and application Download PDFInfo
- Publication number
- CN1772743A CN1772743A CN 200510110010 CN200510110010A CN1772743A CN 1772743 A CN1772743 A CN 1772743A CN 200510110010 CN200510110010 CN 200510110010 CN 200510110010 A CN200510110010 A CN 200510110010A CN 1772743 A CN1772743 A CN 1772743A
- Authority
- CN
- China
- Prior art keywords
- nitrogen
- antifungal compound
- compound
- nitro
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention discloses one kind of antifungal compound in the chemical expression as shown and named as N'-[2-(5-nitro-2H-tetraazol-2-yl)-1-methylethylidene]-4- methylbenzohydrazide. The present invention also discloses its preparation process. In addition, the present invention also discloses one kind of medicine composition with the antifungal compound as active component and the application of the antifungal compound in preparing medicine for treating fungus caused infectious diseases.
Description
Technical field
The present invention relates to a kind of compound, relate in particular to a kind of antifungal compound, the invention still further relates to the preparation method and the application thereof of this antifungal compound in addition.
Background technology
Fungi is a kind of eukaryotic microorganisms that nature extensively exists.Up to now, have been found that more than 200 kind of fungi can cause human body diseases or animals and plants harm (as the rice blast fungus of hazard rice etc.).Fungus-caused human body diseases is divided into shallow to be infected and deep infection.Shallow fungi infestation is mainly caused by Epidermophyton, the mould Pseudomonas of little spore and trichophyton, shows as favus of the scalp, ringworm of the body, tinea versicolor and tinea unguium.The The main pathogenic fungi of deep mycosis then comprises candidiasis, cryptococcus, aspergillus, sporothrix etc., mainly infects digestive tube and respiratory system, and its hazardness is very big, the case fatality rate height.Along with the widespread use of high-efficiency broad spectrum microbiotic, adrenocortical hormone and immunosuppressor clinically, and AIDS, organ-tissue transplant and the increasing gradually of immunocompromised host patients such as chemotherapy, make fungi infestation serious day by day.At present, antifungal drug has become the important component part in the anti-infection drug, in clinical and OTC field a large amount of application is arranged all.
At present clinically antifungal drug to use many be antibiotics, read mycin etc. and azole as grisovin, amphotericin B, gram, as KETOKONAZOL, itraconazole, fluconazole etc.The antimycotic medicine of up-to-date development is the white rhzomorph of thorn, and as Caspofungin (caspofungin), the mechanism of its effect is to suppress the activity of key enzyme-1,3 a beta-glucan synthetic enzyme of fungal cell wall route of synthesis.Owing to all endurance strain can occur after using antifungal drug, so the antifungal drug of development novel type is secular task.
Summary of the invention
One of the technical problem to be solved in the present invention provides a kind of antifungal compound with pharmaceutical use.
Two of the technical problem to be solved in the present invention provides a kind of preparation method of above-mentioned antifungal compound.
Three of the technical problem to be solved in the present invention provides more than one and states the pharmaceutical composition that antifungal compound is an activeconstituents.
Four of the technical problem to be solved in the present invention provides above-mentioned antifungal compound and causes application in the medicine of infectious diseases preparation treatment fungi.
The invention provides the antifungal compound of following chemical formula (I), be N '-(2-{5-nitrogen-tetrazyl }-1-methyl ethylidene)-4-benzoyl hydrazine,
Chemical formula (I)
Wherein R1 represents to select halogen, nitro, C
1～C
6Alkyl;
R2 represents to select halogen, nitro, C
1～C
6Alkyl.
Above-mentioned C
1～C
6Alkyl be meant straight or branched alkyl with 1～6 carbon atom.For example: methyl, ethyl, propyl group, sec.-propyl, butyl, isobutyl-, the tertiary butyl, sec-butyl, amyl group, neo-pentyl, hexyl.
The present invention also provides the preparation method of this antifungal compound, may further comprise the steps: 1-methyl-4-(2-nitrogen) butylene benzene is at catalyzer HNF
2Effect under, introduce another nitrogen at the ortho position of nitrogen, respectively with NaNO
3, HBr, Al
2O
3Reaction is introduced two keys in the position of this nitrogen, further at catalyst n H
2The NHAr effect down with nitro 1,3-ketone-2,3-nitrogen is for butanols reaction generation N '-(2-{5-nitrogen-tetrazyl }-1-methyl ethylidene)-4-benzoyl hydrazine.
Chemical formula (I) antimicrobial compounds can form the pharmaceutically acceptable acid additive salt with organic acid and mineral acid.The N-alkyl derivative and the pharmaceutically acceptable acid additive salt thereof of the pharmacologically acceptable ester derivative of chemical formula (I) compound, ether derivant, formamyl can make by methods known in the art.
The present invention also provides a kind of pharmaceutical composition, and it comprises the above-mentioned chemical formula for the treatment of significant quantity is the antifungal compound of (I), and contains one or more pharmaceutically acceptable carriers.
Above-mentioned acceptable carrier be nontoxic, can assist and use and chemical formula is not had disadvantageous effect for the treatment benefit of the compound of (I).Examples of such carriers can be those skilled in the art common getable any solid excipient, liquid excipient, semisolid excipient or can be the gas vehicle in aerosol combination.The solid pharmaceutical vehicle comprises starch, Mierocrystalline cellulose, talcum, glucose, lactose, sucrose, gelatin, Fructus Hordei Germinatus, rice, flour, chalk, silica gel, Magnesium Stearate, sodium stearate, glycerine stearyl ester, sodium-chlor, anhydrous skimming milk etc.Liquid and semisolid excipient can be selected from glycerine, propylene glycol, water, ethanol and various oil, comprise that those come from the oil of oil, animal, plant or synthetic, for example, peanut oil, soya-bean oil, mineral oil, sesame wet goods, preferred liquid vehicle, especially for Injectable solution, comprise water, salt solution, D/W and glycol.
Compound of the present invention is used with the significant quantity in the treatment, and its method of application can be any accepted method of application that is fit to have similar usefulness reagent.The actual amount of application of compound of the present invention (being active ingredient) depends on many factors, as the age of severity of disease to be treated, treatment target and usefulness, route of administration and the form of relative health degree, employed compound, and other factors.The significant quantity that has in the treatment of compound of chemical formula (I) can be in about every kilogram of acceptor weight range of 0.05-50 milligram every day; Preferred about 0.5-10mg/kg/day.Therefore, use for the people of 70kg body weight, dosage range is most preferably 35-700 milligram every day.
Compound of the present invention is used with pharmaceutical composition by following approach: oral, systemic administration (for example, in transdermal, the nose or use suppository) or parenteral administration (for example, intramuscular, intravenously or subcutaneous).Preferred application process is to use the oral of per daily dose scheme easily, and it can be regulated according to disease degree.
The various formulations of pharmaceutical composition of the present invention can be according to the ordinary method preparation of pharmaceutical field.This compound (activeconstituents) is mixed with one or more carriers, be made into required formulation then, as tablet, pill, capsule, semisolid, powder, slow release formulation, solution, suspension, ingredients, aerosol or the like.
The amount of compound can change in the used four corner of those skilled in the art in the formulation.Usually, (wt%) note contains the compound with chemical formula (I) that accounts for the about 1-99wt% of total formulation in the formulation by weight percentage, and also has one or more suitable drug excipients as equipoise.Preferably, compound exists with the ratio of about 20-70wt%.
The present invention also provides above-mentioned antifungal compound to cause application in the medicine of infectious diseases preparation treatment fungi.
Antifungal compound of the present invention has good broad-spectrum antifungal activity, to common fungi, as S. cervisiae, Aspergillus nidulans and Penicillium marneffei bacterium stronger restraining effect is arranged all, especially important medical mycology-Candida albicans also there is more intense inhibition effect, can be used for treatment or prevent fungus-caused infectious diseases.
Embodiment
Embodiment 1 (preparation of antifungal compound)
The concrete preparation process of antifungal compound (N '-(2-{5-nitrogen-tetrazyl }-1-methyl ethylidene)-4-benzoyl hydrazine) is as follows:
Shown in above-mentioned chemical equation, 1-methyl-4-(2-nitrogen) butylene benzene is at catalyzer HNF
2Effect under, introduce another nitrogen at the ortho position of nitrogen, respectively with NaNO
3, HBr, Al
2O
3Reaction is introduced two keys in the position of this nitrogen, further at catalyst n H
2The NHAr effect down with nitro 1,3-ketone-2,3-nitrogen is for butanols reaction generation N '-(2-{5-nitrogen-tetrazyl }-1-methyl ethylidene)-4-benzoyl hydrazine.
Embodiment 2 (anti-mycotic activity test)
1. experimental strain:
(1) Penicillium marneffei bacterium, this laboratory (2) Candida albicans (CMCC98001) (3) S. cervisiae (Y20) (4) Aspergillus nidulans (M115).
2. substratum:
Penicillium marneffei bacterium and Candida albicans are selected sabouraud culture medium for use.S. cervisiae is selected potato culture for use.Aspergillus nidulans is selected the Cai Shi substratum for use.The concrete prescription of substratum is as follows:
Sabouraud culture medium
Peptone 10g
Glucose 40g
Add water and be made into 1 liter of solution
The Cai Shi substratum
NaNO
3 3g
K
2HPO
4 1g
MgSO
4·7H
2O 0.5g
KCl 3g
FeSO
4·7H
2O 0.01g
Sucrose 30g
Add water and be made into 1 liter of solution
The potato yeast extract medium
Potato (peeling) 200g
Glucose 20g
Yeast extract paste 1.5g
Add water and be made into 1 liter of solution
3. the preparation of bacteria suspension:
Bacterial strain is stored on the inclined-plane semisolid medium, keeps the purifying and the activity (4 ℃ of refrigerator preservations) of bacterium colony.During use with colony inoculation in liquid nutrient medium, 27 ℃ of shaking tables were cultivated 24～48 hours, with hematimeter the concentration of bacteria suspension were controlled at 1～5 * 10
8Between individual/ml.
4. the preparation of antimicrobial compounds:
Compound dissolution in (dimethyl sulfoxide (DMSO)) DMSO, is mixed with 10mg/ml, 0.2 μ m microvoid membrane filtration, the application of sample amount is 10 μ l.
5. the minimum measuring method that suppresses fungi concentration:
Penicillium marneffei bacterium, Candida albicans and S. cervisiae are with reference to the NCCLS scheme.Compound concentration reduces by half and dilutes the growing state of observing bacterium liquid.The last pipe that the NCCLS scheme will not grown fully is judged to be terminal point, adopts 80% to suppress criterion when conditions of streaking is arranged, and the culture in the growth control pipe is carried out dilution in 1: 4, will be judged to be terminal point with the proximate culture tube of its concentration.
Aspergillus nidulans selects for use paper disk method to measure inhibition zone size (scraps of paper diameter 5mm, application of sample amount 10 μ l).Select for use KETOKONAZOL, itraconazole as the positive control medicine.Measure the size of inhibition zone.
All data are all measured behind fungal growth 48h.
6. antimycotic drug effect measurement result:
| Bacterial strain | MIC(mg/ml) |
| The Penicillium marneffei bacterium | 17.8 |
| Candida albicans | 13.1 |
| Yeast saccharomyces cerevisiae | 24.5 |
| Bacterial strain | Antibacterial circle diameter mm | Bacteriostasis |
| Aspergillus nidulans | 17.8 | By force |
Embodiment 3 (preparation of pharmaceutical compositions: tablet)
Adopt hydrophilic auxiliary material (hydroxypropylcellulose and W-Gum), in activeconstituents, add the suitable dilution agent, again by mixing the micronization processes of comminuting method, make medical surfaces cover one deck hydrophilicity condiment, make the particulate homodisperse, improve its dissolution characteristics, helped to improve bioavailability of medicament.A concrete prescription is as follows:
N '-(2-{5-nitrogen-tetrazyl }-1-methyl ethylidene)-4-benzoyl hydrazine 70mg
W-Gum 20mg
Talcum powder 5mg
Hydroxypropylcellulose 5mg
Gross weight 100mg
Embodiment 4 (preparation of pharmaceutical compositions: injection liquid)
Antifungal compound of the present invention is dissolved in the proper amount of water for injection, adds NaCl and injection gac, filter possible impurity promptly.A concrete prescription is as follows:
N '-(2-{5-nitrogen-tetrazyl }-1-methyl ethylidene)-4-benzoyl hydrazine 20mg
NaCl 15ml
Water for injection adds to 100ml
Claims (4)
1. the antifungal compound of following chemical formula (I) expression is N '-(2-{5-nitrogen-tetrazyl }-1-methyl ethylidene)-4-benzoyl hydrazine,
Chemical formula (I)
Wherein: R1 represents halogen, nitro, C
1～C
6Alkyl;
R2 represents halogen, nitro, C
1～C
6Alkyl.
2. the preparation method of the described antifungal compound of claim 1, may further comprise the steps: 1-methyl-4-(2-nitrogen) butylene benzene is at catalyzer HNF
2Effect under, introduce another nitrogen at the ortho position of nitrogen, respectively with NaNO
3, HBr, Al
2O
3Reaction is introduced two keys in the position of this nitrogen, further at catalyst n H
2The NHAr effect down with nitro 1,3-ketone-2,3-nitrogen is for butanols reaction generation N '-(2-{5-nitrogen-tetrazyl }-1-methyl ethylidene)-4-benzoyl hydrazine.
3. pharmaceutical composition, it comprises the described antifungal compound of claim 1.
4. the described antifungal compound of claim 1 causes application in the medicine of infectious diseases the preparation fungi.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005101100101A CN100363353C (en) | 2005-11-03 | 2005-11-03 | Antifungal compound and its prepn process and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005101100101A CN100363353C (en) | 2005-11-03 | 2005-11-03 | Antifungal compound and its prepn process and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1772743A true CN1772743A (en) | 2006-05-17 |
| CN100363353C CN100363353C (en) | 2008-01-23 |
Family
ID=36759904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005101100101A Expired - Fee Related CN100363353C (en) | 2005-11-03 | 2005-11-03 | Antifungal compound and its prepn process and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100363353C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110563642A (en) * | 2019-09-30 | 2019-12-13 | 赵洁 | Antifungal compounds and uses thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3909322A (en) * | 1970-08-03 | 1975-09-30 | Us Navy | Solid gas generating and gun propellant compositions containing a nitroaminotetrazole salt |
-
2005
- 2005-11-03 CN CNB2005101100101A patent/CN100363353C/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110563642A (en) * | 2019-09-30 | 2019-12-13 | 赵洁 | Antifungal compounds and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100363353C (en) | 2008-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1046278C (en) | Azolylamine derivative | |
| CN1237172A (en) | 2R, 4S, R, S- and 2S, 4R, R, S-hydroxyitraconazole and hydroxysaperconazole | |
| US20100098750A1 (en) | Pharmaceutical composition comprising phenylamidine derivative and method of using the pharmaceutical composition in combination with antifungal agent | |
| US20080182885A1 (en) | Modified Azole Compounds As Antifungal and Antibacterial Agents | |
| CN1772743A (en) | Antifungal compound and its prepn process and application | |
| Svejgaard | Double-blind trial of miconzole in dermatomycosis | |
| CN1331855C (en) | Antifungal compound and its prepn process and application | |
| CN1772741A (en) | Antifungal compound CO22 and its prepn process and application | |
| CN1765884A (en) | Antimycotic compound and its preparation method and uses | |
| CN1785996A (en) | Antifungus compound, its preparation method and application | |
| CN1772740A (en) | Antifungal Compound und its prepn process and application | |
| CN1772732A (en) | Antifungal compound and its prepn process and application | |
| CN1772748A (en) | Antifungal compound and its prepn process and application | |
| CN1101189C (en) | Anti-helicobacter pylori compositions containing 1-methylcarbapenem derivatives as the active ingredient | |
| CN100363333C (en) | Antifungus compound, its preparation method and application | |
| CN1772735A (en) | Antifungal compound and its prepn process and application | |
| EP0288019B1 (en) | Beta-cyclodextrin complexes having anti-mycotic activity | |
| CN101279953A (en) | Triazole derivatives used in therapy and medicine salt thereof | |
| EP2650285A1 (en) | Fungicide | |
| WO2009136214A1 (en) | Combination compositions comprising antimycotic agents and statins and the use thereof | |
| CN1102592C (en) | 2R, 4S, S, S- and 2S, 4R, S, S-hydroxyitraconazole | |
| US7704976B2 (en) | Use of N-acetyl-D-glucosamine for preparing medicines for urogenital tract infection's treatment and prevention | |
| CN101798303B (en) | Azole derivatives, preparation method and application thereof | |
| CN111297856B (en) | Medicinal composition for resisting fungal infection and application thereof | |
| JP2561684B2 (en) | Imidazole derivative, process for its production and pharmaceutical composition containing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080123 Termination date: 20101103 |